Mediators of Inflammation
Volume 2009 (2009), Article ID 752406, 13 pages
doi:10.1155/2009/752406
Review Article

The Renin-Angiotensin System Modulates Inflammatory Processes in Atherosclerosis: Evidence from Basic Research and Clinical Studies

Fabrizio Montecucco,1 Aldo Pende,2 and François Mach1

1Division of Cardiology, Foundation for Medical Researches, University Hospital of Geneva, 64 Avenue Roseraie, 1211 Geneva, Switzerland
2Clinic of Internal Medicine I, Department of Internal Medicine, University of Genoa 16132, Genoa, Italy

Received 22 October 2008; Revised 7 January 2009; Accepted 29 January 2009

Academic Editor: Philipp M. Lepper

Copyright © 2009 Fabrizio Montecucco et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. K. Hansson, “Inflammation, atherosclerosis, and coronary artery disease,” The New England Journal of Medicine, vol. 352, no. 16, pp. 1685–1695, 2005. View at Publisher · View at Google Scholar · View at PubMed
  2. P. Libby, “Inflammatory mechanisms: the molecular basis of inflammation and disease,” Nutrition Reviews, vol. 65, pp. S140–S146, 2007. View at Publisher · View at Google Scholar
  3. R. Toni, A. Malaguti, S. Castorina, E. Roti, and R. M. Lechan, “New paradigms in neuroendocrinology: relationships between obesity, systemic inflammation and the neuroendocrine system,” Journal of Endocrinological Investigation, vol. 27, no. 2, pp. 182–186, 2004.
  4. D. S. Jacoby and D. J. Rader, “Renin-angiotensin system and atherothrombotic disease: from genes to treatment,” Archives of Internal Medicine, vol. 163, no. 10, pp. 1155–1164, 2003. View at Publisher · View at Google Scholar · View at PubMed
  5. B. Schieffer and H. Drexler, “Role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases,” The American Journal of Cardiology, vol. 91, no. 12, supplement 1, pp. 12–18, 2003. View at Publisher · View at Google Scholar
  6. R. Tigerstedt and P. G. Bergman, “Nere und Kreislauf,” Skandinavisches Archiv für Physiologie, vol. 8, pp. 223–271, 1898.
  7. F. Fyhrquist and O. Saijonmaa, “Renin-angiotensin system revisited,” Journal of Internal Medicine, vol. 264, no. 3, pp. 224–236, 2008. View at Publisher · View at Google Scholar · View at PubMed
  8. C. Guo, H. Ju, D. Leung, H. Massaeli, M. Shi, and M. Rabinovitch, “A novel vascular smooth muscle chymase is upregulated in hypertensive rats,” The Journal of Clinical Investigation, vol. 107, no. 6, pp. 703–715, 2001. View at Publisher · View at Google Scholar · View at PubMed
  9. G. Nguyen, F. Delarue, C. Burcklé, L. Bouzhir, T. Giller, and J.-D. Sraer, “Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin,” The Journal of Clinical Investigation, vol. 109, no. 11, pp. 1417–1427, 2002. View at Publisher · View at Google Scholar
  10. M. Donoghue, F. Hsieh, E. Baronas, et al., “A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9,” Circulation Research, vol. 87, no. 5, pp. E1–E9, 2000.
  11. S. R. Tipnis, N. M. Hooper, R. Hyde, E. Karran, G. Christie, and A. J. Turner, “A human homolog of angiotensin-converting enzyme: cloning and functional expression as a captopril-insensitive carboxypeptidase,” The Journal of Biological Chemistry, vol. 275, no. 43, pp. 33238–33243, 2000. View at Publisher · View at Google Scholar · View at PubMed
  12. R. D. Stevanovic, D. A. Price, M. C. Lansang, N. D. L. Fisher, L. M. B. Laffel, and N. K. Hollenberg, “Renin release in response to renin system blockade: activation of the renin system in type 1 diabetes mellitus,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 6, no. 2, pp. 78–83, 2005. View at Publisher · View at Google Scholar · View at PubMed
  13. C. M. Ferrario, “Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation,” Hypertension, vol. 47, no. 3, pp. 515–521, 2006. View at Publisher · View at Google Scholar · View at PubMed
  14. L. M. Burrell, J. Risvanis, E. Kubota, et al., “Myocardial infarction increases ACE2 expression in rat and humans,” European Heart Journal, vol. 26, no. 4, pp. 369–375, 2005. View at Publisher · View at Google Scholar · View at PubMed
  15. R. A. Santos and A. J. Ferreira, “Angiotensin-(1-7) and the renin-angiotensin system,” Current Opinion in Nephrology and Hypertension, vol. 16, no. 2, pp. 122–128, 2007. View at Publisher · View at Google Scholar · View at PubMed
  16. Y. Hirono, T. Yoshimoto, N. Suzuki, et al., “Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system,” Endocrinology, vol. 148, no. 4, pp. 1688–1696, 2007. View at Publisher · View at Google Scholar · View at PubMed
  17. K. Tamura, Y. Tanaka, Y. Tsurumi, et al., “The role of angiotensin AT1 receptor-associated protein in renin-angiotensin system regulation and function,” Current Hypertension Reports, vol. 9, no. 2, pp. 121–127, 2007. View at Publisher · View at Google Scholar
  18. L. Gendron, M. D. Payet, and N. Gallo-Payet, “The angiotensin type 2 receptor of angiotensin II and neuronal differentiation: from observations to mechanisms,” Journal of Molecular Endocrinology, vol. 31, no. 3, pp. 359–372, 2003. View at Publisher · View at Google Scholar
  19. L. A. Cassis, S. B. Police, F. Yiannikouris, and S. E. Thatcher, “Local adipose tissue renin-angiotensin system,” Current Hypertension Reports, vol. 10, no. 2, pp. 93–98, 2008. View at Publisher · View at Google Scholar
  20. V. P. Singh, B. Le, R. Khode, K. M. Baker, and R. Kumar, “Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis,” Diabetes, vol. 57, no. 12, pp. 3297–3306, 2008. View at Publisher · View at Google Scholar · View at PubMed
  21. V. P. Singh, K. M. Baker, and R. Kumar, “Activation of the intracellular renin-angiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production,” American Journal of Physiology, vol. 294, no. 4, pp. H1675–H1684, 2008. View at Publisher · View at Google Scholar · View at PubMed
  22. R. Kumar, V. P. Singh, and K. M. Baker, “The intracellular renin-angiotensin system: implications in cardiovascular remodeling,” Current Opinion in Nephrology and Hypertension, vol. 17, no. 2, pp. 168–173, 2008. View at Publisher · View at Google Scholar · View at PubMed
  23. R. E. Schmieder, K. F. Hilgers, M. P. Schlaich, and B. M. Schmidt, “Renin-angiotensin system and cardiovascular risk,” The Lancet, vol. 369, no. 9568, pp. 1208–1219, 2007. View at Publisher · View at Google Scholar · View at PubMed
  24. M. Graninger, R. Reiter, C. Drucker, E. Minar, and B. Jilma, “Angiotensin receptor blockade decreases markers of vascular inflammation,” Journal of Cardiovascular Pharmacology, vol. 44, no. 3, pp. 335–339, 2004. View at Publisher · View at Google Scholar
  25. E. Shagdarsuren, M. Wellner, J.-H. Braesen, et al., “Complement activation in angiotensin II-induced organ damage,” Circulation Research, vol. 97, no. 7, pp. 716–724, 2005. View at Publisher · View at Google Scholar · View at PubMed
  26. M. Epstein, “Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift,” Journal of Hypertension, vol. 19, no. 5, pp. 829–842, 2001. View at Publisher · View at Google Scholar
  27. K. Sean Eardley and P. Cockwell, “Macrophages and progressive tubulointerstitial disease,” Kidney International, vol. 68, no. 2, pp. 437–455, 2005. View at Publisher · View at Google Scholar · View at PubMed
  28. M. Fukuhara, R. L. Geary, D. I. Diz, et al., “Angiotensin-converting enzyme expression in human carotid artery atherosclerosis,” Hypertension, vol. 35, no. 1, part 2, pp. 353–359, 2000.
  29. M. Ohishi, M. Ueda, H. Rakugi, et al., “Enhanced expression of angiotensin-converting enzyme is associated with progression of coronary atherosclerosis in humans,” Journal of Hypertension, vol. 15, no. 11, pp. 1295–1302, 1997. View at Publisher · View at Google Scholar
  30. U. N. Das, “Is angiotensin-II an endogenous pro-inflammatory molecule?,” Medical Science Monitor, vol. 11, no. 5, pp. RA155–RA162, 2005.
  31. C. M. Ferrario and W. B. Strawn, “Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease,” The American Journal of Cardiology, vol. 98, no. 1, pp. 121–128, 2006. View at Publisher · View at Google Scholar · View at PubMed
  32. C.-H. Wang, S.-H. Li, R. D. Weisel, et al., “C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle,” Circulation, vol. 107, no. 13, pp. 1783–1790, 2003. View at Publisher · View at Google Scholar · View at PubMed
  33. K. M. Schmidt-Ott, S. Kagiyama, and M. I. Phillips, “The multiple actions of angiotensin II in atherosclerosis,” Regulatory Peptides, vol. 93, no. 1–3, pp. 65–77, 2000. View at Publisher · View at Google Scholar
  34. S. Keidar, M. Kaplan, A. Hoffman, and M. Aviram, “Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins,” Atherosclerosis, vol. 115, no. 2, pp. 201–215, 1995. View at Publisher · View at Google Scholar
  35. H. Morawietz, U. Rueckschloss, B. Niemann, et al., “Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein,” Circulation, vol. 100, no. 9, pp. 899–902, 1999.
  36. B. A. Schölkens and W. Landgraf, “ACE inhibition and atherogenesis,” Canadian Journal of Physiology and Pharmacology, vol. 80, no. 4, pp. 354–359, 2002. View at Publisher · View at Google Scholar
  37. W. Linz, P. Wohlfart, B. A. Schölkens, R. H. A. Becker, T. Malinski, and G. Wiemer, “Late treatment with ramipril increases survival in old spontaneously hypertensive rats,” Hypertension, vol. 34, no. 2, pp. 291–295, 1999.
  38. G. Wiemer, B. A. Schölkens, R. H. A. Becker, and R. Busse, “Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin,” Hypertension, vol. 18, no. 4, pp. 558–563, 1991.
  39. G. Wiemer, B. A. Schölkens, and W. Linz, “Endothelial protection by converting enzyme inhibitors,” Cardiovascular Research, vol. 28, no. 2, pp. 166–172, 1994. View at Publisher · View at Google Scholar
  40. T. Malinski, S. Mesáros, S. R. Patton, and A. Mesárosová, “Direct measurement of nitric oxide in the cardiovascular system,” Physiological Research, vol. 45, no. 4, pp. 279–284, 1996.
  41. R. Kranzhöfer, M. Browatzki, J. Schmidt, and W. Kübler, “Angiotensin II activates the proinflammatory transcription factor nuclear factor-κB in human monocytes,” Biochemical and Biophysical Research Communications, vol. 257, no. 3, pp. 826–828, 1999. View at Publisher · View at Google Scholar · View at PubMed
  42. R. Kranzhöfer, J. Schmidt, C. A. H. Pfeiffer, S. Hagl, P. Libby, and W. Kübler, “Angiotensin induces inflammatory activation of human vascular smooth muscle cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 7, pp. 1623–1629, 1999.
  43. K. Brand, S. Page, G. Rogler, et al., “Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion,” The Journal of Clinical Investigation, vol. 97, no. 7, pp. 1715–1722, 1996. View at Publisher · View at Google Scholar · View at PubMed
  44. T. J. Guzik and D. G. Harrison, “Endothelial NF-κB as a mediator of kidney damage: the missing link between systemic vascular and renal disease?,” Circulation Research, vol. 101, no. 3, pp. 227–229, 2007. View at Publisher · View at Google Scholar · View at PubMed
  45. N. Henke, R. Schmidt-Ullrich, R. Dechend, et al., “Vascular endothelial cell-specific NF-κB suppression attenuates hypertension-induced renal damage,” Circulation Research, vol. 101, no. 3, pp. 268–276, 2007. View at Publisher · View at Google Scholar · View at PubMed
  46. M. Takahashi, E. Suzuki, R. Takeda, et al., “Angiotensin II and tumor necrosis factor-α synergistically promote monocyte chemoattractant protein-1 expression: roles of NF-κB, p38, and reactive oxygen species,” American Journal of Physiology, vol. 294, no. 6, pp. H2879–H2888, 2008. View at Publisher · View at Google Scholar · View at PubMed
  47. E. Blessing, M. Preusch, R. Kranzhöfer, et al., “Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice,” Atherosclerosis, vol. 199, no. 2, pp. 295–303, 2008. View at Publisher · View at Google Scholar · View at PubMed
  48. G. Chinetti, S. Griglio, M. Antonucci, et al., “Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages,” The Journal of Biological Chemistry, vol. 273, no. 40, pp. 25573–25580, 1998. View at Publisher · View at Google Scholar
  49. H. Kato, J. Ishida, K. Nagano, et al., “Deterioration of atherosclerosis in mice lacking angiotensin II type 1A receptor in bone marrow-derived cells,” Laboratory Investigation, vol. 88, no. 7, pp. 731–739, 2008. View at Publisher · View at Google Scholar · View at PubMed
  50. R. E. Pratt, “Angiotensin II and the control of cardiovascular structure,” Journal of the American Society of Nephrology, vol. 10, pp. S120–S128, 1999.
  51. J. Sadoshima, “Cytokine actions of angiotensin II,” Circulation Research, vol. 86, no. 12, pp. 1187–1189, 2000.
  52. M. Ruiz-Ortega, O. Lorenzo, M. Rupérez, V. Esteban, S. Mezzano, and J. Egido, “Renin-angiotensin system and renal damage: emerging data on angiotensin II as a proinflammatory mediator,” Contributions to Nephrology, vol. 135, pp. 123–137, 2001. View at Publisher · View at Google Scholar
  53. V. J. Dzau, “Mechanism of protective effects of ACE inhibition on coronary artery disease,” European Heart Journal, vol. 19, pp. J2–J6, 1998.
  54. G. B. J. Mancini, “Role of angiotensin-converting enzyme inhibition in reversal of endothelial dysfunction in coronary artery disease,” The American Journal of Medicine, vol. 105, no. 1, supplement 1, pp. 40S–47S, 1998. View at Publisher · View at Google Scholar
  55. K. F. Adams, Jr., “Angiotensin-converting enzyme inhibition and vascular remodeling in coronary artery disease,” Coronary Artery Disease, vol. 9, no. 10, pp. 675–684, 1998.
  56. Y. A. Ding, D. E. MacIntyre, C. J. Kenyon, and P. F. Semple, “Potentiation of adrenaline-induced platelet aggregation by angiotensin II,” Thrombosis and Haemostasis, vol. 54, no. 3, pp. 717–720, 1985.
  57. H. Soejima, H. Ogawa, H. Yasue, et al., “Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction,” Journal of the American College of Cardiology, vol. 34, no. 4, pp. 983–988, 1999. View at Publisher · View at Google Scholar
  58. A. Ichihara, M. Hayashi, N. Hirota, et al., “Angiotensin II type 2 receptor inhibits prorenin processing in juxtaglomerular cells,” Hypertension Research, vol. 26, no. 11, pp. 915–921, 2003. View at Publisher · View at Google Scholar
  59. S. Apostolakis, E. Krambovitis, Z. Vlata, G. E. Kochiadakis, S. Baritaki, and D. A. Spandidos, “CX3CR1 receptor is up-regulated in monocytes of coronary artery diseased patients: impact of pre-inflammatory stimuli and renin-angiotensin system modulators,” Thrombosis Research, vol. 121, no. 3, pp. 387–395, 2007. View at Publisher · View at Google Scholar · View at PubMed
  60. T. Inukai, N. Yoshida, S. Wakabayashi, et al., “Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers effectively and directly potentiate superoxide scavenging by polymorphonuclear leukocytes from patients with type 2 diabetes mellitus,” American Journal of the Medical Sciences, vol. 329, no. 5, pp. 222–227, 2005. View at Publisher · View at Google Scholar
  61. M. Schupp, J. Janke, R. Clasen, T. Unger, and U. Kintscher, “Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity,” Circulation, vol. 109, no. 17, pp. 2054–2057, 2004. View at Publisher · View at Google Scholar · View at PubMed
  62. J. Janke, M. Schupp, S. Engeli, et al., “Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-γ activation,” Journal of Hypertension, vol. 24, no. 9, pp. 1809–1816, 2006. View at Publisher · View at Google Scholar · View at PubMed
  63. N. Jia, H. Okamoto, T. Shimizu, et al., “A newly developed angiotensin II type 1 receptor antagonist, CS866, promotes regression of cardiac hypertrophy by reducing integrin β1 expression,” Hypertension Research, vol. 26, no. 9, pp. 737–742, 2003. View at Publisher · View at Google Scholar
  64. B. A. Schölkens, R. H. A. Becker, and J. Kaiser, “Cardiovascular and antihypertensive activities of the novel non-sulfhydryl converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498),” Arzneimittel-Forschung, vol. 34, no. 10B, pp. 1417–1425, 1984.
  65. P. A. Martorana, H. Ruetten, B. Goebel, et al., “Ramiprilat prevents the development of acute coronary endothelial dysfunction in the dog,” Basic Research in Cardiology, vol. 94, no. 4, pp. 238–245, 1999. View at Publisher · View at Google Scholar
  66. R. H. A. Becker, G. Wiemer, and W. Linz, “Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet,” Journal of Cardiovascular Pharmacology, vol. 18, pp. S110–S115, 1991.
  67. A. V. Chobanian, C. C. Haudenschild, C. Nickerson, and S. Hope, “Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit,” Hypertension, vol. 20, no. 4, pp. 473–477, 1992.
  68. M. Hernández-Presa, C. Bustos, M. Ortego, et al., “Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-κB activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis,” Circulation, vol. 95, no. 6, pp. 1532–1541, 1997.
  69. S. Keidar, J. Attias, R. Coleman, K. Wirth, B. Schölkens, and T. Hayek, “Attenuation of atherosclerosis in apolipoprotein E-deficient mice by ramipril is dissociated from its antihypertensive effect and from potentiation of bradykinin,” Journal of Cardiovascular Pharmacology, vol. 35, no. 1, pp. 64–72, 2000. View at Publisher · View at Google Scholar
  70. M. Akishita, M. Horiuchi, H. Yamada, et al., “Inflammation influences vascular remodeling through AT2 receptor expression and signaling,” Physiological Genomics, vol. 2, no. 1, pp. 13–20, 2000.
  71. M. Akishita, G. Shirakami, M. Iwai, et al., “Angiotensin converting enzyme inhibitor restrains inflammation-induced vascular injury in mice,” Journal of Hypertension, vol. 19, no. 6, pp. 1083–1088, 2001. View at Publisher · View at Google Scholar
  72. R. Candido, K. A. Jandeleit-Dahm, Z. Cao, et al., “Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice,” Circulation, vol. 106, no. 2, pp. 246–253, 2002. View at Publisher · View at Google Scholar
  73. T. Hayek, M. Kaplan, A. Raz, S. Keidar, R. Coleman, and M. Aviram, “Ramipril administration to atherosclerotic mice reduces oxidized low-density lipoprotein uptake by their macrophages and blocks the progression of atherosclerosis,” Atherosclerosis, vol. 161, no. 1, pp. 65–74, 2002. View at Publisher · View at Google Scholar
  74. M. Miyazaki, H. Sakonjo, and S. Takai, “Anti-atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin II antagonist in Cynomolgus monkeys fed a high-cholesterol diet,” British Journal of Pharmacology, vol. 128, no. 3, pp. 523–529, 1999. View at Publisher · View at Google Scholar · View at PubMed
  75. A. V. Chobanian, “The effects of ACE inhibitors and other antihypertensive drugs on cardiovascular risk factors and atherogenesis,” Clinical Cardiology, vol. 13, no. 6, supplement 7, pp. 43–48, 1990.
  76. W. Linz, T. Jessen, R. H. A. Becker, B. A. Schölkens, and G. Wiemer, “Long-term ACE inhibition doubles lifespan of hypertensive rats,” Circulation, vol. 96, no. 9, pp. 3164–3172, 1997.
  77. W. Linz, P. Wohlfart, B. A. Schölkens, T. Malinski, and G. Wiemer, “Interactions among ACE, kinins and NO,” Cardiovascular Research, vol. 43, no. 3, pp. 549–561, 1999. View at Publisher · View at Google Scholar
  78. A. V. Chobanian, C. C. Haudenschild, C. Nickerson, and S. Hope, “Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit,” Hypertension, vol. 20, no. 4, pp. 473–477, 1992.
  79. S. Kim and H. Iwao, “Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases,” Pharmacological Reviews, vol. 52, no. 1, pp. 11–34, 2000.
  80. S. Hope, P. Brecher, and A. V. Chobanian, “Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis,” American Journal of Hypertension, vol. 12, no. 1, pp. 28–34, 1999. View at Publisher · View at Google Scholar
  81. J. Li, N. Hirose, M. Kawamura, and Y. Arai, “Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the cholesterol-fed rabbits,” Atherosclerosis, vol. 143, no. 2, pp. 315–326, 1999. View at Publisher · View at Google Scholar
  82. W. B. Strawn, M. C. Chappell, R. H. Dean, S. Kivlighn, and C. M. Ferrario, “Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia,” Circulation, vol. 101, no. 13, pp. 1586–1593, 2000.
  83. H. Koike, “New pharmacologic aspects of CS-866, the newest angiotensin II receptor antagonist,” The American Journal of Cardiology, vol. 87, no. 8, supplement 1, pp. 33–36, 2001. View at Publisher · View at Google Scholar
  84. A. J. Schuhmacher, C. Guerra, V. Sauzeau, M. Cañamero, X. R. Bustelo, and M. Barbacid, “A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive condition,” The Journal of Clinical Investigation, vol. 118, no. 6, pp. 2169–2179, 2008. View at Publisher · View at Google Scholar · View at PubMed
  85. J. P. van Kats, D. Methot, P. Paradis, D. W. Silversides, and T. L. Reudelhuber, “Use of a biological peptide pump to study chronic peptide hormone action in transgenic mice: direct and indirect effects of angiotensin II on the heart,” The Journal of Biological Chemistry, vol. 276, no. 47, pp. 44012–44017, 2001. View at Publisher · View at Google Scholar · View at PubMed
  86. K. K. Daugherty, “Aliskiren,” American Journal of Health-System Pharmacy, vol. 65, no. 14, pp. 1323–1332, 2008. View at Publisher · View at Google Scholar · View at PubMed
  87. J. Nussberger, J.-F. Aubert, K. Bouzourene, M. Pellegrin, D. Hayoz, and L. Mazzolai, “Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine,” Hypertension, vol. 51, no. 5, pp. 1306–1311, 2008. View at Publisher · View at Google Scholar · View at PubMed
  88. D. N. Müller, W. Derer, and R. Dechend, “Aliskiren—mode of action and preclinical data,” Journal of Molecular Medicine, vol. 86, no. 6, pp. 659–662, 2008. View at Publisher · View at Google Scholar · View at PubMed
  89. T. Imanishi, H. Tsujioka, H. Ikejima, et al., “Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes,” Hypertension, vol. 52, no. 3, pp. 563–572, 2008. View at Publisher · View at Google Scholar · View at PubMed
  90. R. Fischer, R. Dechend, F. Qadri, et al., “Dietary n-3 polyunsaturated fatty acids and direct renin inhibition improve electrical remodeling in a model of high human renin hypertension,” Hypertension, vol. 51, no. 2, pp. 540–546, 2008. View at Publisher · View at Google Scholar · View at PubMed
  91. B. Pilz, E. Shagdarsuren, M. Wellner, et al., “Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats,” Hypertension, vol. 46, no. 3, pp. 569–576, 2005. View at Publisher · View at Google Scholar · View at PubMed
  92. H. Lu, D. L. Rateri, D. L. Feldman, et al., “Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice,” The Journal of Clinical Investigation, vol. 118, no. 3, pp. 984–993, 2008. View at Publisher · View at Google Scholar · View at PubMed
  93. T. Sheth, T. Parker, A. Block, et al., “Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure,” The American Journal of Cardiology, vol. 90, no. 5, pp. 496–500, 2002. View at Publisher · View at Google Scholar
  94. B. Jilma, F. L. Li-Saw-Hee, O. F. Wagner, D. G. Beevers, and G. Y. H. Lip, “Effects of enalapril and losartan on circulating adhesion molecules and monocyte chemotactic protein-1,” Clinical Science, vol. 103, no. 2, pp. 131–136, 2002.
  95. K. K. Koh, J. Y. Ahn, S. H. Han, et al., “Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients,” Journal of the American College of Cardiology, vol. 42, no. 5, pp. 905–910, 2003. View at Publisher · View at Google Scholar
  96. M. Di Napoli and F. Papa, “Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke,” Stroke, vol. 34, no. 12, pp. 2922–2929, 2003. View at Publisher · View at Google Scholar · View at PubMed
  97. J. P. Tsikouris, J. A. Suarez, J. S. Simoni, M. Ziska, and G. E. Meyerrose, “Exploring the effects of ACE inhibitor tissue penetration on vascular inflammation following acute myocardial infarction,” Coronary Artery Disease, vol. 15, no. 4, pp. 211–217, 2004.
  98. B. Schieffer, C. Bünte, J. Witte, et al., “Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease,” Journal of the American College of Cardiology, vol. 44, no. 2, pp. 362–368, 2004. View at Publisher · View at Google Scholar · View at PubMed
  99. D. Fliser, K. Buchholz, and H. Haller, “Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation,” Circulation, vol. 110, no. 9, pp. 1103–1107, 2004. View at Publisher · View at Google Scholar · View at PubMed
  100. J. Trevelyan, D. J. Brull, E. W. A. Needham, H. E. Montgomery, A. Morris, and R. K. Mattu, “Effect of enalapril and losartan on cytokines in patients with stable angina pectoris awaiting coronary artery bypass grafting and their interaction with polymorphisms in the interleukin-6 gene,” The American Journal of Cardiology, vol. 94, no. 5, pp. 564–569, 2004. View at Publisher · View at Google Scholar · View at PubMed
  101. C. Tikiz, O. Utuk, T. Pirildar, et al., “Effects of angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis,” Journal of Rheumatology, vol. 32, no. 11, pp. 2095–2101, 2005.
  102. R. Krysiak and B. Okopień, “Pleiotropic effects of angiotensin-converting enzyme inhibitors in normotensive patients with coronary artery disease,” Pharmacological Reports, vol. 60, no. 4, pp. 514–523, 2008.
  103. V. Dzau and E. Braunwald, “Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement,” American Heart Journal, vol. 121, no. 4, part 1, pp. 1244–1263, 1991. View at Publisher · View at Google Scholar
  104. G. B. J. Mancini, G. C. Henry, C. Macaya, et al., “Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing ENdothelial Dysfunction) study,” Circulation, vol. 94, no. 3, pp. 258–265, 1996.
  105. A. U. Klingbeil, S. John, M. P. Schneider, J. Jacobi, G. Weidinger, and R. E. Schmieder, “AT1-receptor blockade improves augmentation index: a double-blind, randomized, controlled study,” Journal of Hypertension, vol. 20, no. 12, pp. 2423–2428, 2002. View at Publisher · View at Google Scholar
  106. B. Hornig, U. Landmesser, C. Kohler, et al., “Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase,” Circulation, vol. 103, no. 6, pp. 799–805, 2001.
  107. R. E. Schmieder, C. Delles, A. Mimran, J. P. Fauvel, and L. M. Ruilope, “Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes,” Diabetes Care, vol. 30, no. 6, pp. 1351–1356, 2007. View at Publisher · View at Google Scholar · View at PubMed
  108. E. L. Schiffrin, J. B. Park, H. D. Intengan, and R. M. Touyz, “Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan,” Circulation, vol. 101, no. 14, pp. 1653–1659, 2000.
  109. M. Bader and D. Ganten, “Update on tissue renin-angiotensin systems,” Journal of Molecular Medicine, vol. 86, no. 6, pp. 615–621, 2008. View at Publisher · View at Google Scholar · View at PubMed
  110. T. J. Anderson, E. Elstein, H. Haber, and F. Charbonneau, “Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study),” Journal of the American College of Cardiology, vol. 35, no. 1, pp. 60–66, 2000. View at Publisher · View at Google Scholar
  111. F. Perticone, R. Ceravolo, A. Pujia, et al., “Prognostic significance of endothelial dysfunction in hypertensive patients,” Circulation, vol. 104, no. 2, pp. 191–196, 2001.
  112. C. Sierra and A. de la Sierra, “Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers,” Current Opinion in Nephrology and Hypertension, vol. 14, no. 5, pp. 435–441, 2005. View at Publisher · View at Google Scholar
  113. E. M. Lonn, S. Yusuf, V. Dzavik, et al., “Effects of Ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE),” Circulation, vol. 103, no. 7, pp. 919–925, 2001.
  114. S. MacMahon, N. Sharpe, G. Gamble, et al., “Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease,” Journal of the American College of Cardiology, vol. 36, no. 2, pp. 438–443, 2000. View at Publisher · View at Google Scholar
  115. K. K. Teo, J. R. Burton, C. E. Buller, et al., “Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT),” Circulation, vol. 102, no. 15, pp. 1748–1754, 2000.
  116. L. Cashin-Hemphill, G. Holmvang, R. C. Chan, B. Pitt, R. E. Dinsmore, and R. S. Lees, “Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet,” The American Journal of Cardiology, vol. 83, no. 1, pp. 43–47, 1999. View at Publisher · View at Google Scholar
  117. S. E. Nissen, E. M. Tuzcu, P. Libby, et al., “Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial,” The Journal of the American Medical Association, vol. 292, no. 18, pp. 2217–2225, 2004. View at Publisher · View at Google Scholar · View at PubMed
  118. M. H. Olsen, K. Wachtell, K. Neland, et al., “Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy,” Blood Pressure, vol. 14, no. 3, pp. 177–183, 2005. View at Publisher · View at Google Scholar · View at PubMed
  119. M. R. Weir, “Effects of renin-angiotensin system inhibition end-organ protection: can we do better?,” Clinical Therapeutics, vol. 29, no. 9, pp. 1803–1824, 2007. View at Publisher · View at Google Scholar · View at PubMed
  120. C. M. Ferrario, “Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 7, no. 1, pp. 3–14, 2006. View at Publisher · View at Google Scholar · View at PubMed
  121. L. M. Prisant, “Management of hypertension in patients with cardiac disease: use of renin-angiotensin blocking agents,” The American Journal of Medicine, vol. 121, no. 8, supplement 1, pp. S8–S15, 2008. View at Publisher · View at Google Scholar · View at PubMed
  122. S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, and G. Dagenais, “Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients,” The New England Journal of Medicine, vol. 342, no. 3, pp. 145–153, 2000. View at Publisher · View at Google Scholar
  123. P. S. Sever, N. R. Poulter, W. J. Elliott, et al., “Blood pressure reduction is not the only determinant of outcome,” Circulation, vol. 113, no. 23, pp. 2754–2774, 2006. View at Publisher · View at Google Scholar · View at PubMed
  124. K. M. Fox, “Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study),” The Lancet, vol. 362, no. 9386, pp. 782–788, 2003. View at Publisher · View at Google Scholar
  125. E. Braunwald, M. J. Domanski, S. E. Fowler, et al., “Angiotensin-converting-enzyme inhibition in stable coronary artery disease,” The New England Journal of Medicine, vol. 351, no. 20, pp. 2058–2068, 2004. View at Publisher · View at Google Scholar · View at PubMed
  126. E. B. Friedrich, K. K. Teo, and M. Böhm, “ACE inhibition in secondary prevention: are the results controversial?,” Clinical Research in Cardiology, vol. 95, no. 2, pp. 61–67, 2006. View at Publisher · View at Google Scholar · View at PubMed
  127. G. R. Dagenais, J. Pogue, K. Fox, M. L. Simoons, and S. Yusuf, “Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials,” The Lancet, vol. 368, no. 9535, pp. 581–588, 2006. View at Publisher · View at Google Scholar · View at PubMed
  128. S. Yusuf, K. Teo, C. Anderson, et al., “Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial,” The Lancet, vol. 372, no. 9644, pp. 1174–1183, 2008. View at Publisher · View at Google Scholar · View at PubMed
  129. T. L. Ripley and D. Harrison, “The power to TRANSCEND,” The Lancet, vol. 372, no. 9644, pp. 1128–1130, 2008. View at Publisher · View at Google Scholar · View at PubMed
  130. B. Dahlöf, R. B. Devereux, S. E. Kjeldsen, et al., “Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol,” The Lancet, vol. 359, no. 9311, pp. 995–1003, 2002. View at Publisher · View at Google Scholar · View at PubMed
  131. T. Watanabe, T. A. Barker, and B. C. Berk, “Angiotensin II and the endothelium: diverse signals and effects,” Hypertension, vol. 45, no. 2, pp. 163–169, 2005. View at Publisher · View at Google Scholar · View at PubMed
  132. M. Moser, C. Rosendorff, and W. B. White, “Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: is there a difference in response and any advantage to using them together in the treatment of hypertension?,” Journal of Clinical Hypertension, vol. 10, no. 6, pp. 489–496, 2008.
  133. I. H. Schulman and L. Raij, “The angiotensin II type 2 receptor: what is its clinical significance?,” Current Hypertension Reports, vol. 10, no. 3, pp. 188–193, 2008. View at Publisher · View at Google Scholar
  134. F. H. Messerli, B. Williams, and E. Ritz, “Essential hypertension,” The Lancet, vol. 370, no. 9587, pp. 591–603, 2007. View at Publisher · View at Google Scholar · View at PubMed
  135. D. B. Matchar, D. C. McCrory, L. A. Orlando, et al., “Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension,” Annals of Internal Medicine, vol. 148, no. 1, pp. 16–29, 2008.
  136. S. Yusuf, K. K. Teo, J. Pogue, et al., “Telmisartan, ramipril, or both in patients at high risk for vascular events,” The New England Journal of Medicine, vol. 358, no. 15, pp. 1547–1559, 2008. View at Publisher · View at Google Scholar · View at PubMed
  137. J. F. Mann, R. E. Schmieder, M. McQueen, et al., “Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial,” The Lancet, vol. 372, no. 9638, pp. 547–553, 2008. View at Publisher · View at Google Scholar · View at PubMed
  138. C. O. Phillips, A. Kashani, D. K. Ko, G. Francis, and H. M. Krumholz, “Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials,” Archives of Internal Medicine, vol. 167, no. 18, pp. 1930–1936, 2007. View at Publisher · View at Google Scholar · View at PubMed
  139. R. Kunz, C. Friedrich, M. Wolbers, and J. F. E. Mann, “Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease,” Annals of Internal Medicine, vol. 148, no. 1, pp. 30–48, 2008.
  140. J. J. V. McMurray, J. Östergren, K. Swedberg, et al., “Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial,” The Lancet, vol. 362, no. 9386, pp. 767–771, 2003. View at Publisher · View at Google Scholar · View at PubMed
  141. P. Ferrari, H.-P. Marti, M. Pfister, and F. J. Frey, “Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade,” Journal of Hypertension, vol. 20, no. 1, pp. 125–130, 2002. View at Publisher · View at Google Scholar
  142. L. T. Skeggs, Jr., J. R. Kahn, K. Lentz, and N. P. Shumway, “The preparation, purification, and amino acid sequence of a polypeptide renin substrate,” The Journal of Experimental Medicine, vol. 106, no. 3, pp. 439–453, 1957. View at Publisher · View at Google Scholar
  143. H.-H. Parving, F. Persson, J. B. Lewis, E. J. Lewis, and N. K. Hollenberg, “Aliskiren combined with losartan in type 2 diabetes and nephropathy,” The New England Journal of Medicine, vol. 358, no. 23, pp. 2433–2446, 2008. View at Publisher · View at Google Scholar · View at PubMed
  144. D. Westermann, R. Schmieder, H.-P. Schultheiss, and C. Tschöpe, “Renin inhibitors, clinical experience,” Journal of Molecular Medicine, vol. 86, no. 6, pp. 691–695, 2008. View at Publisher · View at Google Scholar · View at PubMed